News & Events about Kempharm Inc.
KemPharm advancing multicenter Phase 2 clinical trial investigating the efficacy and safety of KP1077 for the treatment of idiopathic hypersomnia (IH)CELEBRATION, Fla., Jan. 18, 2023 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a rare disease therapeutics company ...
Expanded roles for Guenther and Mickle support broader evolution into a leading rare disease company CELEBRATION, Fla., Jan. 11, 2023 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a rare disease therapeutics company focused on the development of treatments for rare ...
Trial designed as a multi-center, dose-optimizing, double-blind, placebo-controlled, randomized-withdrawal study to evaluate safety and efficacy of KP1077, as well as to assess the symptoms and severity of brain fog Interim efficacy and safety data expected as early as Q3 2023 CELEBRATION, Fla., Dec...
Globe Newswire
2 months ago
Phase 2 clinical trial investigating KP1077 in patients with IH expected to initiate prior to year-end 2022 CELEBRATION, Fla., Nov. 18, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and ...
KemPharm (NASDAQ:KMPH) is set to give its latest quarterly earnings report on Wednesday, 2022-11-09. Here's what investors need to know before the announcement.
Analysts estimate that KemPharm will report an earnings per share (EPS) of $-0.13.
read more...